“This collaboration further underscores the potential of our differentiated platform.”
— Ajla Hrle, Ph.D., chief business officer, DISCO Pharmaceuticals
DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.
DISCO Pharmaceuticals and AbbVie have entered a strategic collaboration and option-to-license agreement to discover and develop AND-gated bispecific therapeutics for solid tumors with high unmet medical need.1 DISCO will receive $40 million in upfront payments and is eligible for up to $2.5 billion in option, development, and other milestone payments, plus tiered royalties on worldwide net sales.1
“Our AND-gated approach is designed to selectively target tumor cells while sparing healthy tissue,” said Mark Manfredi, Ph.D., CEO of DISCO Pharmaceuticals.1 For AbbVie, the agreement adds access to early-stage targets in an area of oncology where distinguishing tumor cells from healthy tissue is a central design challenge.
“This collaboration further underscores the potential of our differentiated platform.”
— Ajla Hrle, Ph.D., chief business officer, DISCO Pharmaceuticals
The structure is common in platform-based partnerships: a modest upfront payment paired with a much larger pool of contingent milestones. The $40 million upfront payment is less than 2% of the up to $2.5 billion in potential payments, so most of the headline value depends on research outcomes and on AbbVie exercising its options.1
Under the agreement, DISCO will complete specified research activities, after which AbbVie may exclusively license selected programs.1
The collaboration pairs DISCO’s DISCOtech® surfaceome mapping platform and its AND-gated discovery approach with AbbVie’s oncology research and development expertise.1 The portions of the release reviewed do not break out payments by stage, the number of programs, or royalty rates.
DISCO says its DISCOtech platform maps cancer-specific cell-surface expression to identify pairs of targets, with the aim of reducing on-target, off-tumor toxicity.1 That type of toxicity arises when a drug engages a target that is also present on healthy tissue.
As the term is generally used, an AND-gated therapeutic is intended to act only when both members of a target pair appear on the same cell, a pattern the company aims to find in tumor cells but not in normal ones. Manfredi said the platform’s ability to identify tumor-selective target pairs supports therapies with a potentially wider therapeutic window.1
The company develops AND-gated antibody-drug conjugates and T-cell engagers for hard-to-treat tumors, and its lead programs, directed at small cell lung cancer and colorectal cancer, are progressing toward the clinic.1
The agreement follows an earlier 2026 transaction. In January, DISCO announced an exclusive license with Amgen for a cancer target mapped on the cell surface by its platform, with potential total deal value of up to $618 million plus royalties.2
Ajla Hrle, Ph.D., DISCO’s chief business officer, said the AbbVie collaboration complements the company’s internal and partnered pipeline.1 AbbVie, for its part, announced an exclusive licensing agreement in January to develop a novel bispecific antibody for advanced solid tumors.3
Taken together, the transactions suggest continued interest from large drugmakers in bispecific formats for solid tumors. Option-based structures such as the DISCO agreement also let a larger company limit upfront spending while keeping the right to advance programs that mature.
The available documents do not describe how AbbVie would prioritize the DISCO programs against its existing assets.
No clinical data accompany the announcement. The collaboration programs are at the research stage, since DISCO must complete specified research activities before AbbVie can exercise its option.1
The milestone figures are potential payments, not committed revenue, and the portions of the release reviewed do not identify the targets or specific tumor types involved. Because DISCO’s lead programs have not entered the clinic, no peer-reviewed publications or trial registry entries were identified to support efficacy or safety claims for the AND-gated approach, and none are cited here.
The next milestones to watch are completion of DISCO’s research activities and AbbVie’s decisions on which programs to license.
Sources






